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Abstract
Background and purpose: Treatment of intermediate and high-risk prostate cancer with a high BED has been
shown to increase recurrence free survival (RFS). While high dose rate (HDR) brachytherapy, given as a boost is
effective in delivering a high BED, many patients are not candidates for the procedure or wish to avoid an invasive
procedure. We evaluated the use of stereotactic body radiotherapy (SBRT) as a boost, with dosimetry modeled after
HDR-boost.
Material and methods: Fifty patients were treated with two fractions of SBRT (9.5-10.5 Gy/fraction) after 45 Gy
external-beam radiotherapy, with 48 eligible for analysis at a median follow-up of 42.7 months.
Results: The Kaplan-Meier estimates of biochemical control post-radiation therapy (95 % Confidence Interval) at 3, 4
and 5 years were 95 % (81–99 %), 90 % (72–97 %) and 90 % (72–97 %), respectively (not counting 2 patients with a
PSA bounce as failures). RFS (defined as disease recurrence or death) estimates at 3, 4 and 5 years were 92 % (77–
97 %), 88 % (69–95 %) and 83 % (62–93 %) if patients with PSA bounces are not counted as failures, and were 90 %
(75–96 %), 85 % (67–94 %) and 75 % (53–88 %) if they were. The median time to PSA nadir was 26.2 months (range
5.8–82.9 months), with a median PSA nadir of 0.05 ng/mL (range <0.01–1.99 ng/mL). 2 patients had a “benign PSA
bounce”, and 4 patients recurred with radiographic evidence of recurrence beyond the RT fields. Treatment was well
tolerated with no acute G3 or higher GI or GU toxicity and only a single G3 late GU toxicity of urinary obstruction.
Conclusions: SBRT boost is well-tolerated for intermediate and high-risk prostate cancer patients with good
biochemical outcomes and low toxicity.
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Introduction
Patients with intermediate and high-risk prostate cancer
have poorer clinical outcomes than patients with low-
risk prostate cancer, and in need of more intensified
therapeutic options. Although the role of hormone ther-
apy (HT) [1] in increasing recurrence free survival (RFS)
and overall survival (OS) has been well established, the
optimum dose and fractionation of radiation is still be-
ing investigated. Multiple randomized trials have dem-
onstrated an increased RFS with dose escalation [2–4],
albeit no difference in OS. Coupled with a potentially
low alpha-beta ratio [5, 6] for prostate adenocarcinoma,
recent strategies for improving clinical outcomes have
focused on hypofractionated radiotherapy to deliver a
higher bioequivalent dose (BED) over conventionally
fractionated (1.8-2 Gy/fraction) external beam radiother-
apy (CF-EBRT), as well as shortening treatment regi-
mens for increased cost-effectiveness [7]. These efforts
led to use of high dose rate brachytherapy (HDR), both
as a boost [8–10] and as monotherapy [11–14]. Further
supporting the use of hypofractionated radiotherapy, a
lower PSA nadir has been associated with increased free-
dom from biochemical failure [15–18] in prostate cancer,
and the results of studies employing HDR demonstrate
PSA nadirs in the range of 0.1 ng/mL [9], lower than
the 0.5 ng/mL level typically associated with CF-EBRT.
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Unfortunately, HDR requires an invasive operative proced-
ure and many prostate cancer patients are often not candi-
dates due to their age, co-morbidities, or preference not to
have surgery. Therefore, our goal was to develop and dem-
onstrate a non-invasive method of delivering a dose and
fractionation equivalent to an HDR boost using stereotac-
tic body radiotherapy (SBRT) for patients with intermedi-
ate and high-risk prostate cancer.
While SBRT has a long history in the treatment of
CNS and thoracic malignancies, several recent studies
have demonstrated its feasibility and applicability for
treatment of low and intermediate risk prostate cancer
as monotherapy [19–21] with minimal toxicity [22], but
few studies have rigorously examined SBRT in the boost
setting. Our hypothesis was that the SBRT delivered in 2
fractions of 9.5 to 10.5 Gy should result in equivalent
biochemical control and toxicity profile as HDR without
the need for an invasive, operative procedure. Dosimetry
was modeled after RTOG 0321, replicating the rapid de-
livery of high doses, as well as the ability to achieve tight
conformality, sparing nearby normal tissues. This study
differs from previous studies in that we present the re-
sults of SBRT as a boost after CF-EBRT in a higher risk
group of patients and discuss PSA kinetics, biochemical
control, toxicity and patterns of recurrence.
Patients and methods
Ethics, consent, and permissions
Patients with intermediate and high-risk prostate cancer
treated with SBRT as a boost from August 2006 to August
2012 were followed with approval from the XXXX Com-
mittee on Human Research.
Patient selection
Patients with biopsy proven prostate adenocarcinoma
were seen in a multidisciplinary clinic and counseled on
treatment options, including surgery and radiotherapy.
Patients were eligible for this study if they were inter-
mediate (Gleason 3 + 4 or 4 + 3) or high (Gleason ≥8)
grade, node negative, without metastases, and treated
with SBRT as a boost to the prostate after a course of
CF-EBRT to the prostate and seminal vesicles (with or
without whole pelvic radiation). Of the 50 eligible pa-
tients, 48 patients met these criteria and 2 were excluded
due to no available PSA follow-up. T-stage ranged from
T1c to T3b and pre-treatment PSA arranged from 3.6 to
150 ng/mL. Patients were ≥18, with median age of 70
(range 47.1–85.2) years. Patients were eligible for treat-
ment with or without hormone therapy (HT).
Treatment
Of the 48 eligible patients, 45 had information regarding
HT available. The majority (42) of these patients re-
ceived HT, consisting of 2 months of neoadjuvant HT
with Lupron and Casodex or Firmagon, followed by
5 weeks of HT. Thirty of these patients were subse-
quently treated with >3 additional months of adjuvant
HT, with a goal of 4–6 months of HT for all intermedi-
ate risk patients, and 2 years of HT for high risk patients
[23]. HT was discontinued early if the patient experi-
enced side effects significantly affecting their quality of
life. The two SBRT fractions were delivered either con-
secutively or every-other-day [24].
Radiation technique
The specifics of the SBRT technique have been de-
scribed previously [25], but briefly, the dose and frac-
tionation are based on the XXX HDR boost experience
[26], with 9.5 Gy or 10.5 Gy in 2 fractions prescribed to
an isodose of 60-80 %. This corresponds to a biological
equivalent dose (BED) of 278 to 336 with an alpha/beta
of 1.5 or a BED of 158 to 189 with an alpha/beta of 3. A
2 mm planning treatment volume (PTV) expansion is
used, except posteriorly, where the prostate abuts the
rectum, the expansion is 0 mm. The posterior expansion
is reduced to mitigate rectal toxicity. Patients were ini-
tially treated with external beam radiotherapy to the
whole pelvis, extending to between L4/L5 and L5/S1 as
the superior border, and including the internal and ex-
ternal iliacs and obdurator nodes to 45 Gy in 25 frac-
tions. The prostate and seminal vesicles were treated
concurrently to 45–50 Gy using a simultaneous inte-
grated boost (SIB) to the prostate and seminal vesicles of
2 Gy per fraction. The whole pelvis was treated if the
risk of pelvic nodal involvement was >15 % by the Roach
equations [27]. Aside from the use of an SIB, radiother-
apy planning for the conventionally fractionated portion
was done as in RTOG 0321 [8]. Because gold seed fidu-
cials are used for daily alignment, the PTV margin did
not exceed 1 cm. Prior to radiation treatment, 3 fiducial
markers were inserted into the prostate, enabling real-
time tracking of and automatic beam adjustment for in-
ter- and intra-fraction prostate motion, for whole pelvic
RT and SBRT, respectively. Imaging for SBRT was taken
once every 60 s.
Treatment planning was completed with dosimetric
constraints similar to those reported by Fuller [28] for
inverse-planned HDR brachytherapy with PTV V100%
>95 %, D0.1 ml < V120 to the urethra, and rectum and
bladder V75% < 1 mL. In cases were rectum and bladder
doses were not achievable, based on the prostatic inter-
face, doses to rectum and bladder were allowed up to
V75% of 5 mL [29].
Follow-up
Patients were evaluated every 3 months for 2 years, and
then every 6 months up to at least 5 years, and annually
thereafter with PSA and testosterone testing. PSA results
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below the detection limit of the assay were entered as
the respective detection limit (for example 0.1 ng/mL for
a value of <0.1 ng/mL) for data analysis as being the
most conservative estimate. Testosterone testing was
discontinued once it returned into the normal range.
Toxicity was reviewed according to the CTCAE v4.0
scale.
PSA kinetics: nadir, bounce and failure
PSA nadir was determined for patients with sufficient
PSA follow-up, determined by at least 2 PSA measure-
ments after completion of HT or at least 2 PSA mea-
surements for patients not undergoing HT. Of the 48
evaluable patients, 43 patients met these criteria: treat-
ment with HT was unknown for 3 patients, and 2 pa-
tients only had 1 post-HT PSA measurement.
Patients were counted as biochemical failures accord-
ing to the Phoenix definition [30] (PSA >2 ng/mL above
the currently observed PSA nadir). PSA bounce, a be-
nign phenomenon frequently noted after radiotherapy,
was defined as an increase in PSA above the currently
observed nadir greater than 2 ng/ml, with a subsequent
decline in PSA without further treatment. Outcomes
were also computed by counting PSA bounces as failures
with the date of biochemical failure the date of the in-
crease of at least 2 ng/mL above the PSA nadir and also
repeated counting them as benign events.
Statistical analysis
A single cohort of patients was uniformly treated with
CF-EBRT, SBRT and, for almost all, with HT and then
followed prospectively. Descriptive statistics (e.g., means,
medians, proportions) were calculated to characterize
patient, disease and treatment features. The Kaplan-
Meier method was used to estimate the probability of
biochemical control and of RFS with both measured
from the end of RT. Biochemical failure was defined
strictly according to the Phoenix definition and repeated
adjusting for a PSA bounce. RFS failure was the first
event of either any disease recurrence or death. Disease




Of the 48 evaluable patients (Table 1), the median
follow-up was 42.7 months (range 5.3–82.9 months).
The median number of PSA measurements during
follow-up was 8 (range 1–24), with a median of 7 (range
1–19) PSA measurements post-HT for those treated
with any HT. The median pre-treatment PSA was
10.0 ng/mL (range 3.6–150 ng/mL), and 8 of 48 (17 %)
had PSA ≥20 ng/mL. 27 patients (56 %) were Gleason 7,
with 15 patients Gleason 3 + 4 and 12 patients Gleason
4 + 3. Twenty-one patients (44 %) had tumors that were
scored as Gleason 8–10. A significant number (42 %) of
patients had either extracapsular extension (T3a) or
seminal vesicle invasion (T3b) on biopsy or ultrasound.
The remainder of patients were T1c (25 %), T2a (27 %),
and T2b (6 %). All patients underwent conventionally
fractionated external beam radiotherapy and the major-
ity (88 %) received hormone therapy, with 31 % receiving
>6 months of HT. 48 % of patients received a boost of
9.5 Gyx2 fractions, while 52 % received 10.5 Gyx2
fractions.
Biochemical control
Of the 48 evaluable patients, 6 patients had a PSA rise
≥2 ng/mL above the current nadir, but two of these pa-
tients subsequently had a decline in PSA and which was
then determined to be a PSA bounce. Follow-up is too
short to estimate overall survival with only 2 observed
Table 1 Baseline patient and treatment characteristics: (n = 48)
Median Age (range) 70 years (47.1 – 85.2)
Median Pre-Treatment PSA (range) 10.0 ng/mL (3.6 – 150.0)
≥20 ng/mL 8 (17 %)
Gleason Score
7 27 (56 %)
3 + 4 15 (31 %)
4 + 3 12 (25 %)
8-10 21 (44 %)
T Stage
T1c 12 (25 %)
T2a 13 (27 %)
T2b 3 (6 %)
T3a,b 20 (42 %)
# High Riska 34 (71 %)
Median Duration HT (range) 6 months (0 – 28)
None 3 (6 %)
3 months 12 (25 %)
4–6 months 15 (31 %)
7–12 months 8 (17 %)
24–28 months 7 (15 %)
Unknown 3 (6 %)
CTV Dose
19 Gy 23 (48 %)
21 Gy 25 (52 %)
Median Follow-up (range) 42.7 months (5.3 – 82.9)
# PSA Follow-up Measurements
Median (range) 8.5 (1 – 24)
Median Post HT (range) 7 (1 – 19)
aHigh Risk is defined as pretreatment ≥20 ng/mL, GS 8–10 or T stage 3
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deaths as of this analysis, without either patient showing
any evidence of disease.
The Kaplan-Meier estimates of biochemical no evi-
dence of disease (bNED) with 95 % confidence intervals
are 95 % (81–99 %) at 3 years, 90 % (72–97 %) at 4 years,
and 90 % (72–97 %) at 5 years. If PSA bounces are
counted as failures, then the estimates of bNED are
93 % (78–98 %) at 3 years, 88 % (69–96 %) at 4 years,
and 82 % (61–93 %) at 5 years.
Recurrence free survival
The Kaplan-Meier estimates of RFS estimates at 3, 4 and
5 years were 92 % (77–97 %), 88 % (69–95 %) and 83 %
(62–93 %) if patients with PSA bounces are not counted
as failures, and 90 % (75–96 %), 85 % (67–94 %) and
75 % (53–88 %) if they were.
PSA nadir
A lower PSA nadir is associated with improved clinical
outcomes, and therefore we evaluated both the PSA
nadir and time to nadir. For 43 patients with sufficient
PSA follow-up to evaluate a PSA nadir, defined as having
at least 2 PSA measurements without any HT or after
completing HT, the median time to nadir was 26.2 months
(range: 5.8–82.9 months), and the median PSA nadir was
0.05 ng/mL (range <0.01–1.99 ng/mL). The majority of
these patients (72 %), had a PSA nadir ≤0.10 ng/mL, and
only 2 patients (5 %) had a PSA nadir >1 ng/mL and both
of these patients had not received any HT. These esti-
mates of PSA nadir and time to nadir do not change if
PSA bounces are not counted as failures because the
values change for only 1 of the 2 patients with a PSA
bounce.
The use of hormone therapy had a noticeable effect on
PSA nadir: the 3 patients who did not receive any HT
had the highest PSA nadir for the study cohort (0.97,
1.51 and 1.99 ng/mL).
PSA bounce
For the 2 patients who experienced a benign PSA bounce,
initial failure by the Phoenix definition occurred at 50 and
11 months, while the duration for bNED was 54 and 58,
months, respectively, when considering the bounce as be-
nign. The initial PSA nadirs for these two patients were
0.46 and 0.55, and the maximum PSA reflecting the
bounce, 4.9, and 5.54 ng/ml, respectively. These values
subsequently declined to 1.3, and 0.04 ng/ml, respectively,
at last follow-up.
Patterns of failure
Of the 4 patients who recurred biochemically (without
PSA bounce), all recurred outside the radiation field, in-
cluding 2 with peri-aortic nodal involvement, 33 and
21 months after completion of SBRT. These nodes were
discovered on imaging 3 and 9 months, respectively,
after biochemical failure. The third patient developed a
bone metastasis at T2 79 months after radiation. A
fourth patient, with T3a Gleason 4 + 5 disease, developed
metastatic disease to the bone discovered on PET/CT
52 months after SBRT and 4 months after biochemical
failure.
Toxicity
No patient in this study had acute Grade 3 or higher geni-
tourinary (GU) or gastrointestinal (GI) toxicity (Table 2).
Twenty-three (48 %) and 18 (37 %) patients had an acute
grade 1 (G1) and G2 GU toxicity, while only 20 (42 %)
and 5 (10 %) patients had an acute G1 and G2 GI toxicity,
respectively. A single case of late G3 GU toxicity occurred
with urinary obstruction, but resolved. 10 and 12 patients
had late G1 and 2 GU toxicity, respectively, and the ma-
jority (82 %) of these patients had acute G1 or 2 GU tox-
icity as well. Late GI toxicity was rare, with only 6 patients
(12.5 %) having late grade 1 toxicity, and only 2 of these
patients had acute GI toxicity. There was no G2 or higher
late GI toxicity.
Discussion
The patients studied here represent an older, higher risk
cohort, often typical of patients who have advanced
prostate cancer and are not surgical candidates. The me-
dian age was 70 and 71 % of patients were high-risk, as
defined by D’Amico et al. [23]. Notably, almost half of
patients (44 %) had Gleason 8 disease or higher, or




Grade 0 7 (15 %) -
Grade 1 23 (48 %) 16
Grade 2 18 (37 %) 17 (1 dose de-escalation)
Acute GI:
Grade 0 23 (48 %)
Grade 1 20 (42 %) 10
Grade 2 5 (10 %) 1
Late GU:
Grade 0 25 (52 %) -
Grade 1 10 (21 %) 3
Grade 2 12 (25 %) 9
Grade 3 1 (2 %) 1 (Obstruction)
Late GI:
Grade 0 42 (87.5 %) -
Grade 1 6 (12.5 %) 1
Acute Toxicity: Maximum grade observed during the first 6 months from start
of protocol therapy
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extension outside of the prostate (42 % T3a/b), with
67 % of patients having one or both features. Consistent
with the proven role of hormone therapy in increasing
overall survival in high-risk patients, 88 % received hor-
mone therapy.
The results presented here compare favorably with
historical series studying intermediate and high-risk pa-
tients using CF-EBRT. In RTOG 8610 [31] only 40 % of
patients were bNED at 5 years, while RTOG 9202 [32]
and EORTC 22863 [33] found a 5 year disease free sur-
vival rate of 46.4 and 76 %, respectively. With the caveat
that these studies contained a different patient popula-
tion, occurred pre-dose escalation, and defined biochem-
ical failure in different ways, our 5 year estimates of
bNED of 90 % and RFS of 83 %, compare favorably to
the these trials.
The high rate of biochemical control for this relatively
high-risk cohort may also be due to the incorporation of
a hypofractionated boost, leveraging the low α/β ratio of
prostate cancer. The possibility of a low α/β ratio in
prostate cancer has prompted clinical investigations util-
izing a hypofractionated boost delivered with HDR, pro-
viding a more appropriate comparison for the results
presented here. The Seattle Prostate Institute reported a
15 year biochemical control rate of 80 and 68 % for
intermediate and high-risk groups, respectively [34],
treated with a permanent seed implant after pelvic radio-
therapy. Another randomized study comparing HDR
boost of 8 Gyx2 fractions versus CF-EBRT showed PSA
relapse-free survival of 97 and 96 % for intermediate and
high-risk patients, respectively [35]. At UCSF, 165 pa-
tients treated with a HDR boost (9.5 Gyx2 fractions or 6
Gyx3 fractions) [36] showed PSA control rates of 87 and
93 % for the two dose subsets, respectively, at 5 years. A
dose escalation study [37] showed BED > 268 Gy (α/β =
1.2) delivered with HDR yielded a 10 year biochemical
control rate of 81 %. A combined analysis of HDR boost
patients [38] showed that biochemical control at 5 years
was 88 and 69 % for patients with one and two risk fac-
tors (stage ≥ T2b, GS ≥ 7, and PSA ≥ 10 ng/mL), respect-
ively. Therefore, the results presented here indicate
comparable biochemical outcomes to recent HDR-boost
series that employed a similar dose and fractionation.
The results presented here also compare favorably
with recent SBRT series in prostate cancer, with regards
to both biochemical control and toxicity (Table 3). A
multi-institutional analysis [19] of localized prostate can-
cer treated with SBRT, with a median follow-up of
36 months, found the 5-year biochemical relapse free
survival rate was 84 and 81 % for intermediate and high-
risk prostate cancer patients, respectively. Similar to the
patients studied here, Katz [39] reported outcomes using
SBRT as a boost for intermediate and high-risk patients,
finding 3-year biochemical control rates of 89.5 and
77.7 %, respectively. Treatment was well tolerated, with
only 6.8 % acute G2 GU toxicity and 6.7 % G2 rectal
toxicity. Albeit with a follow-up of only 33 months, the
long-term toxicity results are encouraging, with a rate of
Table 3 Comparison of outcomes of contemporary SBRT
Author (Year) N Pt type Dose FU (yr) Toxicity Outcome Ref
King (2009) 67 Low-risk; PSA < 10,
G < = 3 + 4; <= T2a/b
7.25 x 5 2.7 GU: Grade 4 (0 %) 3 (3 %), 2 (5 %),
and 1 (23 %) respectively.
Rectal Grade 3 (0 %), 2 (2 %),
and 1 (12.5 %).
(5 years) 94 % relapse
free survival
[24]
Boike (2011) 45 PSA≤ 20, G ≤ 7, ≤T2b 9-10 x 5 2.5 GI: 3 (2 %), 2 (16 %);
GU: 3 (4 %); 2 (27 %)
[48]
Chen (2013) 100 Low/intermediate
risk (8 high)
7-7.25 x 5 2.3 GU ≥2 (31 %); GI≥ 2 (1 %) (2 years) 99 % (31 % bounce,
21 % late transient urinary
symptom flare)
[21]
Katz (2010) 73 Intermediate/High Risk 6-7 x 3 (Boost) 2.75 2 (7 %) (3 years) 89.5 %
(Intermediate); 77.7 % (high)
[39]
Suy (2010) 24 6.5 x 3 (Boost) 0.8 GU 2 (13 %); GI 2 (4 %) [49]
Katz (2010) 304 Low/intermediate/high 7-7.25 x 5 2.5 AcuteGU 2 (4.7 %);
GI 2 (4 %);
Late
GU 3 (0.5 %); 2 (6 %)
GI 2 (3 %)
4 failures (16 % bounce) [50]
Jabarri (2012) 38 Low/intermediate/high 9.5 x 4 (mono);
9.5 x 2 (boost)
1 Acute
GU 2 (42 %); GI 2 (11 %)
Late






and high-risk (11 %).
36.25 Gy in
4–5 fx
3 (5 years) 93 %
(16 % bounce)
[19]
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91.8 % for G2 or higher rectal toxicity-free survival. Fu-
ture efforts at assessing toxicity should include patient
reported outcomes.
Although long-term results are needed to definitively
establish the efficacy of SBRT as a boost modality in
these patients, the recent introduction of SBRT into the
clinic limits the available follow-up. However, the PSA
nadir provides insight into the long-term biochemical
control rate [40], with lower PSA nadir associated with
increased freedom from biochemical failure [15–18]. In
a matched-pair analysis [41], the PSA nadir from EBRT +
HDR was 0.4 ng/ml, significantly lower than the 1.1 ng/ml
with EBRT alone. Similarly, the University of Berlin [42]
showed that 53 % of patients treated with HDR boost
reached a PSA nadir of ≤0.5 ng/ml and the William
Beaumont Hospital [43] reported that 70 % of patients
had a PSA nadir of <0.5 ng/mL. Our results using SBRT
compare favorably with these, with a PSA nadir of
0.05 ng/mL and a median time to nadir of 26 months. Of
note, the PSA nadir continues to decline with longer
follow-up. In a subset of these patients, we previously re-
ported a median PSA nadir of 0.1 ng/mL at a median
follow-up of 33.4 months [44]. When analyzing the PSA
kinetics of SBRT monotherapy, PSA nadir also declines
with longer follow-up [45]. Additional follow-up may yield
an even lower median PSA nadir for this study cohort.
The toxicity reported here is similar to other series
using EBRT with HDR and SBRT. RTOG 0321 used an
HDR boost of 9.5 Gyx2 and noted 2.5 % late G3 and
greater GU and GI toxicities. An updated analysis
showed that 28 of 121 evaluable cases have grade 2+ GU
toxicity [46], with V120 and greater associated with in-
creased urethral toxicity. To mitigate this, the urethra is
contoured on the co-registered MRI to implement ur-
ethral sparing. Using HDR accepted dose tolerances,
only a single G3 urinary toxicity was observed. A recent
summary of over 1000 patients undergoing SBRT mono-
therapy reported only minimal decline in quality of life
measures after treatment, with reported grade 3 toxicity
ranging between 1 and 3 % [47].
There are several limitations to this study. Although
this is a relatively high-risk, older group of patients, it
includes both intermediate and high-risk patients. Al-
though testosterone was measured until it returned to
the normal range, the use of HT and the slow recovery
of testosterone may reduce the PSA value. Furthermore,
no regular imaging of the prostate or re-biopsy was
done, and therefore local control rates are only based on
lack of PSA failure, and local recurrences cannot be cat-
egorically excluded. As with all non-randomized studies,
patient selection can introduce bias, but this often results
in patients with more adverse features being included in
the study population due to the inclusion of older, non-
operable candidates. Although the median follow-up is
about 4 years, longer follow-up is needed to definitively
assess the efficacy of SBRT in the boost setting.
Conclusion
Hypofractionated SBRT is a feasible method to deliver
the boost dose in an older, high-risk cohort, as demon-
strated here. Although longer follow-up is needed, the
preliminary biochemical control is similar to treatment
with an HDR boost and to date, in patients with bio-
chemical failure, there are no radiographically docu-
mented local failures. The low median PSA nadir of
0.05 ng/mL following SBRT is an improvement over
standard EBRT and comparable to brachytherapy, adding
to the evidence that prostate cancer has a low α/β and
benefits from hypofractionated treatment. SBRT is a vi-
able option to deliver the boost dose, achieving promis-
ing biochemical control and reduced PSA nadir with
minimal toxicity without a surgical procedure.
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CF-EBRT: Conventionally fractionated external beam radiotherapy;
DFS: Disease-free survival; EBRT: External beam radiotherapy; HDR: High dose
rate brachytherapy; SBRT: Stereotactic body radiotherapy; WPRT: Whole
pelvic radiotherapy.
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